Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado
2024年7月24日 - 3:50PM
Prota Therapeutics, an Australian biotechnology company focused on
the development of novel oral immunotherapy treatments against
peanut allergy, today announced the appointment of Patrick Machado
as a Chair to its Board of Directors, effective immediately.
Patrick is a highly respected figure in the biotech industry
with a proven track record of success in identifying and developing
technologies that can improve patient care. He brings over 30 years
of experience in the biotech sector and a deep understanding of the
scientific and regulatory processes involved in bringing new
treatments to market.
“We are thrilled to welcome Patrick to the Prota Board,” said
Professor Mimi Tang, CEO of Prota Therapeutics. “His extensive
experience and dedication to patient well-being perfectly align
with Prota’s mission. We are confident that his insights and
guidance will be instrumental in pushing Prota forward as we strive
to bring this life-changing peanut allergy treatment to
patients.”
Patrick’s arrival will strengthen Prota Therapeutics’ Board and
support the company as they progress to the Phase 3 clinical
investigation of its PRT120 oral therapy for peanut allergy, after
having secured US$21 million in funding earlier in the year to
finance its drug development program leading up to a Phase 3
trial.
A Passion for Parental Safety and Improving Patient
Lives
Patrick’s decision to join the Prota board was driven by his
strong belief in the Company's mission: to develop a safe and
effective treatment for peanut allergies, a condition that affects
millions of children and their families worldwide.
“As a parent, I can only imagine the immense anxiety faced by
families living with severe peanut allergies,” said Patrick.
“When assessing companies, I prioritise two factors: the
potential to meaningfully elevate patient care and the
qualifications and passion of the scientific founders. Prota excels
on both fronts. Prota’s mission to significantly reduce, or even
eliminate, that fear for families is truly inspiring. The
groundbreaking data generated by the Prota team fuels my confidence
in achieving this goal. I’m honored to join the Prota family and
contribute to this critical mission.”
About Patrick Machado
Patrick has had an impressive 30-year career in the
biotechnology industry. He co-founded the U.S. biotechnology
company Medivation, Inc., which successfully developed and launched
Xtandi, one of the top-selling prostate cancer treatments globally.
Medivation was sold to U.S. pharmaceutical company Pfizer, Inc. in
2016. Since 2014, Mr. Machado has served on the boards of
approximately 20 biotechnology companies across the U.S., Canada,
Europe and Australia, including Endocyte (sold to Novartis in
2018), Principia Biopharma (sold to Sanofi in 2020) and Turning
Point Therapeutics (sold to Bristol Myers Squibb in 2022).
About Prota Therapeutics
Prota Therapeutics is an Australian, proprietary limited,
privately-held biotech company established in 2016 to develop and
commercialize novel oral immunotherapy treatments. Prota holds an
exclusive license to proprietary food immunotherapy technology,
developed at the Murdoch Children’s Research Institute. The company
is, in part, a OneVenture’s Healthcare Fund III investment. This
fund was established with investment in part from the Australian
Commonwealth Government through the BioMedical Translation Fund
initiative. Prota Therapeutics has its headquarters in Melbourne,
Australia. More information: https://protatherapeutics.com
Media Contacts: Prota
Therapeutics – WE CommunicationsAna Luiza
Harropanah@we-worldwide.com+61 0452510255
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/badded48-2c34-499d-8619-658f1869de74